Gainers Kandi Technologies Group Inc shares gained 34.34 percent to close at $7.98 on Wednesday after the company reported NHTSA approval of 2 electric vehicle models. Arca Biopharma Inc shares surged 31.27 percent to close at $0.5080 on Wednesday after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support a
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer...
The post Smart drug shows promise for metastatic triple-negative breast cancer appeared first on European Pharmaceutical Review.
With this approval, HUMIRA has become the first treatment indicated for HS in Japan, and is now approved for 11 indications in Japan. The approval of this additional indication is based on the data from a Japanese Phase III study and overseas clinical trials. In the clinical trial conducted in Japan, the percentage of patients who achieved the prim
-AbbVie, a global, research and development-based biopharmaceutical company, announced an agreement was reached with the pan- Canadian Pharmaceutical Alliance regarding MAVIRET?, a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes 2. MAVIRET is the only 8- week, pan-genotypic treat
Analyst Ratings For Abeona Therapeutics Inc (NASDAQ:ABEO) Today, HC Wainwright reiterated its Buy rating on Abeona Therapeutics Inc (NASDAQ:ABEO) with a price target of $30.00. There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy w
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8 th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m....
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, announces it has been recognized by the TSX Venture Exchange in its 2019 Venture 50, a ranking of the strongest companies on TSX Venture Ex
-Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the Company will be presenting at the following investor conferences:. 8th Annual Leerink Global Healthcare Conference on February 27th, 2019 at...
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE study of plazomicin in a Letter to the Editor. Achaogen's EPIC...
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 EPIC study of ZEMDRI. Wagenlehner, M.D., Director, Clinic for Urology,
SEATTLE- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA Program, which aims to evaluate the effectivenes
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office located at 1777 Sentry Parkway West in Blue Bell, Pa. The approximately 12,000 square-feet office space will serve as.
-Adamas Pharmaceuticals, Inc., a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Companys Founder, Chairman and Chief Executive, is scheduled to present at the following two investor conferences:. Leerink Partners Global Healthcare...
SAN DIEGO- Adamis Pharmaceuticals Corporation announced today that the article entitled' Higher doses of naloxone are needed in the synthetic opioid era' has been published in the peer reviewed journal Substance Abuse Treatment, Prevention, and Policy. According to statistics published by the Centers for Disease Control and Prevention in 2017, drug
This partnership brings together critical capabilities to allow the commencement of Adial's planned initial Phase 3 trial, with Catalent providing packaging and distribution. Catalent has a robust, global network, with the presence in Europe and the U.S. to provide flexible, integrated clinical supply services for investigational medicinal products
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public offering of 2,475,000 shares of its common stock and warrants to purchase up to 1,856,250 shares of the Company's common stock. Maxim Group LLC is acting as the book-r
WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024" reports to its database. WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to
-ADVANZ PHARMA Corp., an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with continued access to high quality, niche established medicines, today announced it intends to release its fourth quarter and 2018 financial results before market open on Thursday, March 14, 2
Merck& Co. disclosed Tuesday its cancer drug Keytruda failed a Phase 3 study in advanced liver cancer, less than four months after the immunotherapy gained an accelerated approval for a similar indication. In a statement, Merck Research Laboratories chief medical officer Roy Baynes called the efficacy results "generally consistent with findings fro
MORTSEL, Belgium, Feb. 21, 2019/ PRNewswire/. DR 800* offers one solution for radiography, fluoroscopy, tomography and advanced clinical applications. Tomosynthesis algorithms reconstruct images very quickly. MUSICA? Digital Tomosynthesis software processes the tomographic slices that are synthesized from a single tomographic sweep..
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
BioCorRX, a small Anaheim company, believes it can help break this vicious cycle, and the National Institute on Drug Abuse is inclined to agree. The institute part of the National Institutes of Health has awarded BioCorRX a grant to help develop a naltrexone implant to treat what is officially called "opioid use disorder." BioCorRx in Anaheim,
Alembic Pharmaceuticals Limited today announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application Acetazolamide Extended-Release Capsules, 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product Diamox Sequels, 500 mg, of Teva Branded Pharmaceutical...
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019/ PRNewswire/ Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potenti
WESTMINSTER- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 clinical..
